Updates to the Management of HR-Positive, HER2-Negative Breast Cancer ...
May 31, 2024 · Metastatic hormone receptor–positive, HER2-negative breast cancer treatment is increasingly individualized as more of the tumor landscape is described and targeted therapies …
Neratinib Plus Capecitabine for the Treatment of Her2-Negative ...
This phase II trial tests how well neratinib in combination with capecitabine works in treating patients with HER2-negative breast cancer that has spread from where it first started (primary …
The Role of Continuing CDK4/6 Inhibition After Disease …
Oct 22, 2025 · Although 3 CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) are approved for hormone receptor–positive, HER2-negative metastatic breast cancer, questions …
Novel Drug Combination Shows Promise for Advanced HER2-Negative Breast …
Feb 14, 2024 · A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators …
Targeting HER2-low in metastatic breast cancer: an evolving treatment …
The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are leading to a shift in both the classification and treatment of human epidermal growth factor …
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative …
May 13, 2025 · In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational burden …
FDA approves imlunestrant for ER-positive, HER2-negative, ESR1 …
Sep 25, 2025 · FDA also approved the Guardant360 CDx assay as a companion diagnostic device to identify patients with breast cancer with ESR1 mutations for treatment with …
Olema Oncology Announces New Data from the Phase 1b/2 Trial …
Oct 20, 2025 · It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) …
Datroway demonstrated an unprecedented median overall survival ...
Oct 19, 2025 · Datroway is approved in more than 35 countries/regions worldwide for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-negative (IHC 0, …
Overall survival with sacituzumab govitecan in hormone receptor ...
Oct 21, 2023 · Sacituzumab govitecan demonstrated significant progression-free survival benefit over chemotherapy in the phase 3 TROPiCS-02 trial in patients with pretreated, endocrine …